Model uses sociodemographic factors to predict aromatase inhibitor non-adherence risk

A new risk model uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors for breast cancer are at significantly higher risk of stopping that therapy early (non-adherence).

The work will be presented in a poster spotlight discussion session at the 2023 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 6th.

The authors analyzed data from the SWOG S1105 clinical trial, including measures of patient adherence to aromatase inhibitor (AI) therapy for hormone-sensitive breast cancer. They created a model composed of individual sociodemographic and financial factors – as well as measures of area-level deprivation and rural/urban location – that were statistically significantly associated with  adherence. The presence of each additional risk factor increased the risk of non-adherence by 47 percent. Those with more than two risk factors had a 64 percent greater likelihood of AI non-adherence.

Lead author on the abstract is Dawn L. Hershman, MD, MS, who will present the work at SABCS.

“We recognize that non-adherence to endocrine therapy is multifactorial. Predicting who is at risk will help us target personalized interventions to the right patients,” said Hershman, who is American Cancer Society Professor of Medicine and Epidemiology at Columbia University Irving Medical Center, deputy director of the Herbert Irving Comprehensive Cancer Center, and group co-chair-elect of SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

About two-thirds of patients treated for breast cancer have hormone receptor-positive disease, meaning the growth of their tumors is driven by estrogen or progesterone. Women with this type of cancer are often prescribed drugs that reduce hormone production, such as aromatase inhibitors (AIs). 

Clinical trials have shown that taking an AI daily for several years can significantly reduce the chance of the breast cancer returning. But for a variety of reasons, including common side effects such as bone pain and hot flashes, many patients stop taking their AIs early.

The risk model being presented at SABCS was developed using data from the SWOG S1105 clinical trial, a randomized study that enrolled more than 700 post-menopausal women to test whether text message reminders could improve adherence to AI therapy. All patients had been prescribed AI therapy for breast cancer, and they were assessed on the study every three months for continued use of their AI pills. Primary results of the trial, which Hershman led, were published in the Journal of Clinical Oncology in 2020.

To develop the predictive model, the researchers analyzed a set of demographic and financial measures collected when patients joined the S1105 trial. They found four of these measures had statistically significant associations with increased non-adherence to AI therapy: younger age, less education, lower out-of-pocket costs, and living in urban areas. In their data, race and ethnicity were not associated with non-adherence.

“These findings provide further evidence that an individual’s social and economic background can contribute vital information in predicting the course of their treatment,” said senior author Joseph Unger, PhD, associate professor at the Fred Hutchinson Cancer Center and a biostatistician and health services researcher with the SWOG Cancer Research Network. 

“This recognition is important for establishing early on which patients are at much greater risk of non-adherence to long-term AI therapy, which could allow more effective targeting of interventions.”

The authors conclude that such interventions, in addition to steps to relieve symptoms from side effects, should focus on structural barriers in patients at highest risk.
 

Study S1105 was funded by the NIH/NCI through grant UG1CA189974 and in part by the Conquer Cancer Foundation and the Breast Cancer Research Foundation and was conducted through NCI Community Oncology Research Program (NCORP).

In addition to Drs. Hershman and Unger, co-authors include Anna Moseley, MS, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Kathryn B. Arnold, MS, SWOG Statistics and Data Management Center; Julie R. Gralow, MD, American Society of Clinical Oncology; Alfred I. Neugut, MD, PhD, Herbert Irving Comprehensive Cancer Center, Columbia University ; Scott D. Ramsey, MD, PhD, Fred Hutchinson Cancer Center; and N. Lynn Henry, MD, PhD, University of Michigan Rogel Cancer Center.

SWOG Cancer Research Network is part of the National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Program and is part of the oldest and largest publicly funded cancer research network in the nation. SWOG has 20,000 members in 45 states and nine other countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org, and follow us on Twitter (X) at @SWOG.
 

Reference:

PS04-08: “Sociodemographic Risk Factors and Prediction of Aromatase Inhibitor Non-Adherence in Women with Breast Cancer Enrolled in SWOG S1105,” Hershman, DL, et al. 2023 San Antonio Breast Cancer Symposium.